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While statins significantly reduce cholesterol levels and thereby reduce the risk of car-
diovascular disease, the development of myopathy with statin use is a significant clinical 
side effect. Recent guidelines recommend increasing inclusion criteria for statin treatment 
in diabetic individuals; however, the impact of statins on skeletal muscle health in those 
with diabetes (who already suffer from impairments in muscle health) is ill defined. Here, 
we investigate the effects of fluvastatin treatment on muscle health in wild type (WT) and 
streptozotocin (STZ)-induced diabetic mice. WT and STZ-diabetic mice received diet 
enriched with 600 mg/kg fluvastatin or control chow for 24 days. Muscle morphology, 
intra and extracellular lipid levels, and lipid transporter content were investigated. Our 
findings indicate that short-term fluvastatin administration induced a myopathy that 
was not exacerbated by the presence of STZ-induced diabetes. Fluvastatin significantly 
increased ectopic lipid deposition within the muscle of STZ-diabetic animals, findings 
that were not seen with diabetes or statin treatment alone. Consistent with this obser-
vation, only fluvastatin-treated diabetic mice downregulated protein expression of lipid 
transporters FAT/CD36 and FABPpm in their skeletal muscle. No differences in FAT/
CD36 or FABPpm mRNA content were observed. Altered lipid compartmentalization 
resultant of a downregulation in lipid transporter content in STZ-induced diabetic skeletal 
muscle was apparent in the current investigation. Given the association between ectopic 
lipid deposition in skeletal muscle and the development of insulin-resistance, our findings 
highlight the necessity for more thorough investigations into the impact of statins in 
humans with diabetes.
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inTrODUcTiOn
Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase, thereby inhibiting cholesterol biosyn-
thesis and LDL formation with great efficacy. As reductions in circulating LDL cholesterol levels 
greatly reduce atherosclerotic cardiovascular disease (ASCVD) risk, statins are among the most 
widely prescribed pharmaceuticals in the world (1–3). While considerable evidence supports 
Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovas-
cular disease; GPS, gastrocnemius, plantaris, soleus; H&E, hematoxylin–eosin; IMCL, intramyocellular lipid; ORO, oil red O; 
STZ, streptozotocin; T1DM, type 1 diabetes mellitus; TA, tibialis anterior; WT, wild-type.
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the benefits of these cholesterol-lowering drugs in reducing 
ASCVD risk, statin therapies have also been associated with 
serious side effects, such as myopathy. Recent reports estimate 
up to 25% of statin users experience some form of myopathic/
myalgia symptoms, ranging from muscle soreness to severe 
rhabdomyolysis (4–6). Despite these concerns, the American 
College of Cardiology (ACC) and American Heart Association 
(AHA) 2013 guidelines recommend that all diabetic individu-
als over the age of 40 be prescribed statins regardless of their 
ASCVD risk (5).
Muscle from those with Type 1 diabetes mellitus (T1DM) 
exhibits myopathic features; a complication termed diabetic 
myopathy (7). Decreases in muscle mass (8) and reduced 
myofiber size (9), translating to muscle weakness and reduced 
physical capacity (10, 11) have all been shown in individuals 
with T1DM. While new statin therapy guidelines were imple-
mented to reduce ASCVD risk in diabetic individuals, it has 
not yet been elucidated if the combination of T1DM and statin 
administration exacerbates the myopathy resultant from each 
factor alone. To that end, we fed wild-type (WT) and strepto-
zotocin (STZ)-treated mice (T1DM mouse model) a control or 
fluvastatin-enriched diet for a period of 24 days and harvested 
their skeletal muscle to assess metabolic and morphologic 
characteristics.
MaTerials anD MeThODs
animal handling and Tissue collection
Experimentation was approved by the McMaster University 
Animal Research Ethics Board, in accordance with the Canadian 
Council for Animal Care guidelines. At 10–12  weeks of age, 
male C57BL6/J mice (Jackson Laboratories, Bar Harbor, ME, 
USA) were randomly assigned into WT or STZ-diabetic 
[single 150 mg/kg intraperitoneal STZ injection (Calbiochem, 
San Diego, CA, USA)] groups. Six weeks after diabetes onset 
(blood glucose >14  mM), animals were further subdivided 
and assigned to receive either diet enriched with 600  mg/kg 
fluvastatin or control chow [D12081101, D12450K, respectively; 
OpenSource Diets, New Brunswick, NJ, USA]. Diet was admin-
istered ad  libitum for 24  days, after which all animals were 
euthanized, and tissues were embedded and/or snap frozen for 
later analyses.
histochemical and immunofluorescent 
analysis
Frozen TA (tibialis anterior) muscle sections were stained via 
hematoxylin–eosin (H&E) to quantify centrally located nuclei, 
necrotic fibers, and myofiber areas. Laminin and dystrophin (both 
1:250; Abcam, Cambridge, UK) fluorescent co-stain was used 
to determine the number of split myofibers. Oil Red O (ORO) 
staining was used to quantify intramyocellular lipid density. 
Analysis of perilipin (1:200; Cell Signaling, Danvers, MA, USA) 
was used for determination of ectopic lipid droplet number and 
size per unit area. All imaging and analysis was undertaken on a 
Nikon 90i microscope using Nikon NIS-Elements ND2 software 
(Melville, NY, USA).
Western Blotting
Gastrocnemius, plantaris, and soleus (GPS) muscle was 
homogenized in NP40 Lysis Buffer supplemented with phenyl-
methylsulfonylfluoride and Protease Inhibitor Cocktail. Western 
blotting was undertaken as previously described (12) using anti-
FAT/CD36 (Santa Cruz, Dallas, TX, USA) and anti-FABPpm 
(generous gift from J. Calles-Escandon, Wake Forest University, 
NC, USA) and primary antibodies and appropriate horserad-
ish peroxidase-conjugated secondary antibodies. Bands were 
quantified via densitometry (Alpha Innotech Fluorchem HD2, 
ThermoFisher Scientific, Waltham, MA, USA) with equal load-
ing confirmed by PonceauS staining (Sigma-Aldrich, St. Louis, 
MO, USA).
real-time Pcr
Total RNA was extracted from GPS using Trizol reagent and 
reversed transcribed into cDNA. Changes in mRNA expres-
sion were determined using real-time qPCR and Taqman gene 
expression assays for mouse CD36 (Mm_00432403_m1), 
FABPpm (Mm00494703_m1), and GAPDH (4352932E) (Applied 
Biosystems, Foster City, CA, USA) as previously described in 
Ref. (13).
statistics
All statistical analyses were performed using Prism 6 (GraphPad 
Software, La Jolla, CA, USA). Statistical significance was deter-
mined via unpaired t-test, and defined as p ≤ 0.05.
resUlTs
analysis of Myopathy
Centrally nucleated, necrotic and split myofibers were evaluated 
and summated as “myopathic fibers” to characterize myopathy. 
Fluvastatin administration increased total myopathic fibers in TA 
muscle from both WT (Figure 1A) and STZ-treated (Figure 1B) 
mice. Representative images are shown in Figures 1D–H. Although 
myopathy was observed in both WT and STZ muscle as a result 
of fluvastatin administration, no difference in the severity of 
myopathy was noted between WT and STZ muscle (Figure 1C). 
When compared to control-treated muscle, fiber cross-sectional 
area was significantly reduced following fluvastatin treatment in 
both WT (Figure 1I) and STZ (Figure 1J) muscle, supporting a 
greater presence of atrophied, myopathic fibers. Representative 
images are shown in Figures 1L–O. Once again, no differences in 
myofiber area were noted between WT and STZ muscle as a result 
of fluvastatin treatment (Figure 1K).
extracellular and intramyocellular 
lipid analysis
Histological examination by H&E staining revealed transparent 
globules adjacent to muscle fibers that appeared to be ectopic 
lipid deposits, most notably in fluvastatin-treated groups. To 
verify this hypothesis, perilipin (member of a family of proteins 
that associate with the surface of lipid droplets/adipocytes) analy-
sis was conducted. Quantification demonstrated a significant 
elevation in ectopic lipid content and size within STZ-diabetic 
FigUre 1 | short-term fluvastatin administration causes hallmark phenotypes of myopathy. No differences in severity of myopathy, however, are noted 
between WT- and STZ-diabetic skeletal muscle. When compared to their control treated counterparts, fluvastatin administration results in an increased amount of 
total myopathic fibers in both WT (a) and STZ (B) muscle. No differences in severity of myopathy as a result of fluvastatin administration, however, are noted 
between WT and STZ skeletal muscle (p = 0.38) (c). A red arrowhead, indicating an example of a split fiber, is shown in (D). Representative myopathic images for 
each group are shown in (e–h). White arrowheads indicate centrally nucleated fibers, while yellow arrowheads indicate necrotic fibers. A decrease in average fiber 
area as a result of fluvastatin administration is noted in both WT (i) and STZ (J) muscle, and, once again, no differences in the degree of this decrease are noted 
between WT and STZ muscle (p = 0.37) (K). Images depicting representative fiber size for each group are shown in (l–O). For (a,B,i,J), white bars indicate control 
treatment, and black bars indicate fluvastatin treatment. For (c,K), Striped bars indicate percent change in fluvastatin-treated WT muscle relative to control-treated 
WT muscle, and checked bars indicate percent change in fluvastatin-treated STZ muscle relative to control-treated STZ muscle. Scale bar in D = 50 μm. Scale bar 
in (e–h,l–O) = 100 μm. *Significant differences (p ≤ 0.05). All data presented as mean ± SEM. n = 5–6 for each bar in (a–c). n = 4–6 for each bar in (i–K).
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muscle following fluvastatin administration, an effect that was 
not observed in other groups (Figures 2A–D).
With respect to intramyocellular lipid droplets (IMCLs), no 
differences in content were evident in WT muscle with treatment 
(Figure  2E). In contrast, fluvastatin-treated STZ-diabetic mice 
exhibited significantly reduced IMCL content relative to their 
diabetic counterparts (Figures 2F–H).
lipid Transporter analysis
When compared to control-treated muscle, no differences in 
FAT/CD36 content were apparent in WT muscle as a result of flu-
vastatin administration (Figure 2I), while STZ-diabetic muscles 
displayed decreases in FAT/CD36 content with fluvastatin treat-
ment (Figure 2J). FABPpm analysis revealed elevations in protein 
content in WT muscle as a result of fluvastatin administration 
(Figure  2K), and, mirroring FAT/CD36 analysis, decreases in 
FABPpm content in fluvastatin-treated STZ muscle (Figure 2L).
In order to ascertain if fluvastatin treatment was affecting the 
transcriptional regulation of lipid transporters, mRNA analysis 
was conducted. No differences in FAT/CD36 or FABPpm mRNA 
content were observed between groups (Figures 2M–Q).
DiscUssiOn
Recent ACC/AHA guidelines recommend the widespread use 
of statin therapy as a primary means to reduce ASCVD risk in 
all persons over 40  years old with diabetes mellitus (5). While 
statin therapy lowers ASCVD risk, these HMG-CoA reductase 
inhibitors are also associated with a risk of myotoxicity (4), and 
their impact on skeletal muscle health in those with T1DM has 
FigUre 2 | short-term fluvastatin administration affects lipid and fatty acid transporter content in sTZ-diabetic skeletal muscle. Whereas fluvastatin 
administration causes no modifications in ectopic lipid content of WT muscle (p = 0.31) (a), STZ muscle displays significant increases in ectopic lipid content [and 
ectopic lipid size (p < 0.05)] as a result of fluvastatin administration (B). Representative perilipin-stained (ectopic lipid) images of STZ control and fluvastatin-treated 
STZ (STZ + Fl) muscle are depicted in (c,D), respectively. Oil Red O (ORO) analysis, once again, reveals no differences in WT muscle IMCL content as a result of 
fluvastatin administration (p = 0.41) (e). STZ muscle, however, (F) displays significant decreases in IMCL density in the presence of fluvastatin. Representative IMCL 
images of STZ control and fluvastatin-treated STZ muscle are depicted in (g,h), respectively. No differences in FAT/CD36 content were apparent in WT muscle as a 
result of fluvastatin administration (p = 0.47) (i), while STZ muscle displayed decreases in FAT/CD36 content with treatment (J). FABPpm, contrastingly, was 
elevated in WT muscle as a result of fluvastatin administration (K), and, once more, STZ muscle displayed decreases in FABPpm content with fluvastatin treatment 
(l). A representative immunoblot, including loading control (PonceauS), is shown in (M). No differences in FAT/CD36 or FABPpm mRNA expression were observed 
with treatment (n–Q); graphs depicted as fold-change relative to respective control. White bars indicate control treatment, black bars indicate fluvastatin treatment. 
*Significant differences (p < 0.05). All data presented as mean ± SEM. n = 5–6 for each bar in (a–Q). Scale bar = 100 μm in (c,D,g,h).
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not yet been fully examined. Many rodent studies investigat-
ing the impact of statins on myopathy have utilized long-term 
administration or statins with a stronger myotoxic profile (14). 
The present study, however, utilized short-term exposure of 
fluvastatin; a statin generally agreed to have a low clinical risk 
of myotoxicity (15). Despite a low myotoxic profile, fluvastatin 
has been reported to activate the NLRP3 inflammasome and 
induce adipose tissue insulin resistance in obese animals at 
5Rebalka et al. Impact of Statin Therapy on Diabetic Muscle
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levels comparable to, or greater than lovastatin, atorvastatin, 
and simvastatin (16).
Here, we report that short-term fluvastatin administration 
resulted in a myopathic phenotype, the characteristics of which 
were not exacerbated with STZ-induced diabetes. Statin-treated 
diabetic mice did however demonstrate a significant increase in 
the presence of skeletal muscle ectopic lipid droplets, an observa-
tion that was not present in statin-treated, non-diabetic mice. In 
support of this observation, statin-treated diabetic mice displayed 
significant decreases in lipid transporter content within their 
skeletal muscle. These findings raise the possibility that statin 
administration in T1DM humans could contribute to the impair-
ments in skeletal muscle health, including insulin resistance (17).
Type 1 diabetes mellitus negatively impacts skeletal muscle 
health, a complication referred to as diabetic myopathy (7). 
Here, we chose an early time point of T1DM progression, where 
certain myopathic characteristics (centrally located nuclei, split 
and necrotic fibers) would be minimal, thus allowing us to assess 
if statin treatment exacerbated the progression of diabetic myo-
pathy. In contrast to our hypothesis, statin-treated mice did not 
display a worsened myopathy in the presence of diabetes. Future 
studies using a more established diabetic myopathy, or a statin 
with a stronger myotoxicity profile [e.g., simvastatin (15)], would 
address this question more fully.
While we hypothesized that statin administration would worsen 
the quality of diabetic muscle, the profound effects of statin treat-
ment on ectopic lipid droplet formation within diabetic muscle 
was an unexpected and, to our knowledge, novel finding. Muscles 
of T1DM mice have elevated IMCL content with a concomitant 
increase in lipid transporters [present study, (12)]. Interestingly, 
when diabetic mice are on statin therapy, a significant rise in lipid 
content outside of the myofibers was noted without an increase 
in IMCLs, indicating potential complications with myofiber lipid 
transport. Supportive of this altered lipid compartmentalization, 
interrogation of lipid transporters demonstrated that FAT/CD36 
and FABPpm protein content was significantly downregulated in 
statin-treated diabetic skeletal muscle. FAT/CD36 and FABPpm 
are integral membrane proteins that, following the appropriate 
stimulus, are mobilized from their intracellular pools to be inte-
grated into the plasma membrane (18). As mRNA content of these 
proteins was not different between groups, these findings suggest 
the observed changes in lipid transporter content to be post-
translational in nature. Specifically, the observed lipidopathy is 
hypothesized to be a result of attenuated transporter palmitoyla-
tion, impairing transporter mobilization and ultimate metabolic 
functionality. Indeed, previous work has implicated statins in the 
reduction of palmitoylation (19) as well as in the impairment of 
protein trafficking and localization of FAT/CD36 (20).
Elevated lipid transporter content is important in the muscles 
of poorly controlled Type 1 diabetic individuals to provide an 
adequate fuel supply in the absence of insulin (and resultant 
lack of glucose uptake). The present data would suggest that the 
increased lipid availability observed in diabetes coupled with the 
statin-mediated decreases in lipid transporter availability would 
hinder lipid uptake and result in an accumulation of ectopic lipids 
within the diabetic muscle. Given the association between skeletal 
muscle ectopic lipids and the development of insulin resistance, 
the adverse effects of statin administration in the presence of 
overt diabetes could have profound effects on glycemic control in 
those with insulin-dependent diabetes mellitus.
Future studies should focus on identifying whether statin 
treatment in humans with diabetes decreases lipid transporter 
availability and, in turn, increases the presence of ectopic lipids 
within skeletal muscle. Furthermore, to complement the findings 
of this investigation, future studies should investigate the exacer-
bation of lipid deposition in other tissues (heart and liver) as lipid 
accumulation in these tissues has been linked to dysfunction and 
insulin resistance (21).
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